Lyra Therapeutics reports FY2022 net loss $55.3M; cash $97.9M; ENLIGHTEN I on track for mid-2023 enrollment completion

Lyra Therapeutics, Inc.

Net loss for FY2022 $55.3M vs $43.5M in 2021; Q4 net loss $14.2M.
Cash and investments $97.9M as of Dec 31, 2022; sufficient into mid-2024.
ENLIGHTEN I Phase 3 enrollment completion on track for mid-2023; ENLIGHTEN II resume enrollment Q2 2023 (ahead of prior Q3 2023).
BEACON Phase 2 data for LYR-220 expected Q4 2023.
Transitioned manufacturing in-house to prepare for commercial production.

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.4

Lyra Therapeutics, Inc. reported the fourth quarter and full year ended December 31, 2022 results: net income Net loss for the fourth quarter and full year ended December 31, 2022 was $14.2 million and $55.3 million, respectively.

Period: the fourth quarter and full year ended December 31, 2022
Net income: Net loss for the fourth quarter and full year ended December 31, 2022 was $14.2 million and $55.3 million, respectively
Result: reported results

Exact text from the filing

Lyra Therapeutics, Inc. (the “Company”) announced its financial results for the year ended December 31, 2022.

View on SEC.gov

20 earnings releases filed in the last 30 days. Browse all earnings releases →

Lyra Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0000950170-23-010621

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.